Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety evaluation of rituximab therapy for refractory pemphigus
jRCTs031180405Completed
- Sponsor
- Nippon Zenyaku Kogyo Co., Ltd.
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of rituximab in pemphigus, sponsored by Nippon Zenyaku Kogyo Co., Ltd. Primary endpoint: 24-week safety after rituximab therapy. Started May 2017; status: completed.
02
Drugs
rituximab
03
Conditions
pemphigus
Beyond the preview
Go deeper on jRCTs031180405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180405.